Twist Bioscience director sells 2,500 shares

Twist Bioscience Corp director Melissa A. Starovasnik sold 2,500 shares of Common Stock in an open-market transaction at $68.00 per share.

Rhea-AI Filing Summary

Twist Bioscience Corp director Melissa A. Starovasnik sold 2,500 shares of Common Stock in an open-market transaction at $68.00 per share. The trade took place on May 28, 2026 and was reported as a direct ownership transaction.

Following this sale, she directly holds 22,222 shares of Twist Bioscience Corp. The filing notes that the transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 22, 2025, indicating the sale was scheduled in advance.

Insider Trade Summary 10b5-1

Net Seller: 2,500 shares

Net Sell 1 txn

Insider Starovasnik Melissa A.

Role Director

Sold 2,500 shs ($170K)

Type	Security	Shares	Price	Value
Sale	Common Stock	2,500	$68.00	$170K

Holdings After Transaction: Common Stock — 22,222 shares (Direct)

Footnotes (1)

1. F1. The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on November 22, 2025.

Key Figures

Shares sold: 2,500 shares Sale price: $68.00 per share Shares held after transaction: 22,222 shares +1 more

4 metrics

Shares sold 2,500 shares Open-market sale on May 28, 2026

Sale price $68.00 per share Price for reported 2,500-share sale

Shares held after transaction 22,222 shares Direct ownership following sale

Net shares sold 2,500 shares Net change in reported period

Key Terms

Rule 10b5-1 trading plan, open-market sale, Common Stock, Form 4

4 terms

Rule 10b5-1 trading plan regulatory

"The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

open-market sale financial

"transaction_action": "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Common Stock financial

"security_title": "Common Stock""

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Form 4 regulatory

"The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Twist Bioscience (TWST) disclose in this Form 4?

Twist Bioscience reported that director Melissa A. Starovasnik sold 2,500 shares of Common Stock. The sale occurred on May 28, 2026 at $68.00 per share in an open-market transaction, reducing but not eliminating her direct stake.

How many Twist Bioscience (TWST) shares did the director sell and at what price?

Director Melissa A. Starovasnik sold 2,500 shares of Twist Bioscience Common Stock at $68.00 per share. This open-market sale represents a single reported transaction on May 28, 2026, according to the Form 4 filing information.

How many Twist Bioscience (TWST) shares does the director hold after the sale?

After the reported sale, director Melissa A. Starovasnik holds 22,222 Twist Bioscience Common Stock shares directly. This post-transaction holding reflects her remaining stake as disclosed in the Form 4, which details ownership following the May 28, 2026 sale.

Was the Twist Bioscience (TWST) insider sale made under a Rule 10b5-1 plan?

Yes. The Form 4 states the transaction was executed under a Rule 10b5-1 trading plan adopted on November 22, 2025. Such pre-arranged plans schedule trades in advance, helping separate routine portfolio activity from discretionary timing decisions by insiders.

What type of transaction is reported for Twist Bioscience (TWST) in this Form 4?

The filing reports an open-market sale of Common Stock, coded as “S.” This code indicates a sale in the open market or a private transaction, distinguishing it from option exercises, tax withholding, gifts, or other non-market-related share transfers.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/01/2026 - 04:05 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Starovasnik Melissa A.

(Last) (First) (Middle)

C/O TWIST BIOSCIENCE CORPORATION

681 GATEWAY BOULEVARD

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Twist Bioscience Corp [ TWST ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/28/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/28/2026		S(1)		2,500	D	$68	22,222	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on November 22, 2025.

Remarks:

	/s/ Kendra Fox, as Attorney-in-Fact for Melissa A. Starovasnik	06/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)